Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015

Published: Nov, 2015 | Pages: 177 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chronic Kidney Disease (Chronic Renal Failure) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Kidney Disease (Chronic Renal Failure) Overview 8
Therapeutics Development 9
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview 9
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis 10
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies 11
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes 13
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies 18
Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes 21
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 22
Acceleron Pharma, Inc. 22
Angion Biomedica Corp. 23
Apceth GmbH & Co. KG 24
Astellas Pharma Inc. 25
Bayer AG 26
Bio-inRen 27
Boryung Pharmaceutical Co., Ltd. 28
Complexa, Inc. 29
Eli Lilly and Company 30
Evotec AG 31
Intercept Pharmaceuticals, Inc. 32
Isis Pharmaceuticals, Inc. 33
La Jolla Pharmaceutical Company 34
Lupin Limited 35
Nippon Zoki Pharmaceutical Co., Ltd. 36
OPKO Health, Inc. 37
Otsuka Holdings Co., Ltd. 38
Prismic Pharmaceuticals, Inc. 39
Prolong Pharmaceuticals 40
ProMetic Life Sciences Inc. 41
Reata Pharmaceuticals, Inc. 42
Red Glead Discovery AB 43
RegenMedTX, LLC 44
Resverlogix Corp. 45
Sphaera Pharma Pvt. Ltd. 46
Stelic Institute & Co. 47
Thrasos Therapeutics Inc. 48
Toray Industries, Inc. 49
VBS Pharmaceuticals 50
Vicore Pharma AB 51
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Combination Products 53
Assessment by Target 54
Assessment by Mechanism of Action 57
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
(palmidrol + silibinin) - Drug Profile 64
ANG-3070 - Drug Profile 65
ANG-3586 - Drug Profile 66
ANG-4011 - Drug Profile 67
apabetalone - Drug Profile 68
APC-611 - Drug Profile 71
AS-2444697 - Drug Profile 72
ASP-6858 - Drug Profile 73
bardoxolone methyl - Drug Profile 74
BR-05001 - Drug Profile 77
BRN-1889 - Drug Profile 78
C-21 - Drug Profile 79
calcium succinate - Drug Profile 81
CAR Peptide - Drug Profile 82
Cardiotoxin - Drug Profile 83
Cell Therapy for Chronic Kidney Disease - Drug Profile 84
CXA-10 - Drug Profile 85
Drug for Kidney Diseases - Drug Profile 86
Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Oncology - Drug Profile 87
finerenone - Drug Profile 88
INT-767 - Drug Profile 89
ISIS-FXIRx - Drug Profile 91
KBP-5074 - Drug Profile 92
LJPC-101 - Drug Profile 93
LY-3016859 - Drug Profile 94
LY-3113593 - Drug Profile 95
NZ-419 - Drug Profile 96
PBI-4050 - Drug Profile 98
PBI-4419 - Drug Profile 100
Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 101
rivaroxaban - Drug Profile 102
Sanguinate - Drug Profile 108
Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile 110
Small Molecule to Inhibit Sodium-Phosphate Cotransport for CKD and Hypertension - Drug Profile 111
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 112
Small Molecules for Chronic Kidney Disease - Drug Profile 113
Small Molecules for Chronic Kidney Disease - Drug Profile 114
Small Molecules to Inhibit SphK2 for Oncology, Kideny Disease, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile 115
sotatercept - Drug Profile 116
SP-20103 - Drug Profile 118
SPR-494 - Drug Profile 119
STNM-310 - Drug Profile 120
Synthetic Peptides for Chronic Kidney Disease - Drug Profile 121
TNT-009 - Drug Profile 122
tolvaptan - Drug Profile 123
torsemide ER - Drug Profile 126
TRC-101 - Drug Profile 127
Vida-5 - Drug Profile 128
Chronic Kidney Disease (Chronic Renal Failure) - Recent Pipeline Updates 129
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 163
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 165
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 166
Featured News & Press Releases 166
Appendix 172
Methodology 172
Coverage 172
Secondary Research 172
Primary Research 172
Expert Panel Validation 172
Contact Us 172
Disclaimer 173

List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2015 13
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 16
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Development, H2 2015 20
Comparative Analysis by Unknown Stage Development, H2 2015 21
Products under Development by Companies, H2 2015 22
Products under Development by Companies, H2 2015 (Contd..1) 23
Products under Development by Companies, H2 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2015 25
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Acceleron Pharma, Inc., H2 2015 26
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp., H2 2015 27
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Apceth GmbH & Co. KG, H2 2015 28
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc., H2 2015 29
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H2 2015 30
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bio-inRen, H2 2015 31
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015 32
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa, Inc., H2 2015 33
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Eli Lilly and Company, H2 2015 34
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H2 2015 35
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015 36
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 37
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by La Jolla Pharmaceutical Company, H2 2015 38
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Limited, H2 2015 39
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H2 2015 40
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health, Inc., H2 2015 41
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 42
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals, Inc., H2 2015 43
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals, H2 2015 44
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc., H2 2015 45
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals, Inc., H2 2015 46
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Red Glead Discovery AB, H2 2015 47
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by RegenMedTX, LLC, H2 2015 48
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp., H2 2015 49
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015 50
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Stelic Institute & Co., H2 2015 51
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Thrasos Therapeutics Inc., H2 2015 52
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries, Inc., H2 2015 53
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VBS Pharmaceuticals, H2 2015 54
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H2 2015 55
Assessment by Monotherapy Products, H2 2015 56
Assessment by Combination Products, H2 2015 57
Number of Products by Stage and Target, H2 2015 59
Number of Products by Stage and Mechanism of Action, H2 2015 62
Number of Products by Stage and Route of Administration, H2 2015 65
Number of Products by Stage and Molecule Type, H2 2015 67
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Recent Pipeline Updates, H2 2015 133
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H2 2015 167
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects (Contd..1), H2 2015 168
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H2 2015 169